---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009737"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:59:30.776880+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Scienture gets exclusive US rights to commercialize REZENOPY naloxone nasal spray from Kindeva

## Summary
- Exclusive 10-year US license to commercialize REZENOPY (naloxone HCl 10mg) from Kindeva; term expires 10 yrs from first commercial sale.
- Supply price $9.20/unit; profit-sharing 10% of net sales (8% upon generic entry); additional 5% until $12.8M NDA cost recovered.
- Milestone payments up to $10M based on net sales targets; $1M upfront milestones due in stages.
- Minimum order: 3 batches of 450,000 units/year from 2027 or $1.242M/year; $189M total naloxone market (IQVIA MAT Dec 2024).

## SEC filing metadata
- accession: 0001493152-25-009737
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/0001493152-25-009737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009737
- JSON: https://secwatch.observer/filing/0001493152-25-009737.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.